BOLT News and Press, Bolt Biotherapeutics Inc. From 02/28/23

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annu...

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Bolt Metals Corp. (CSE: BOLT) (FSE: A2QEUB) (OTCQB: PCRCF) (" Bolt " or the " Company ") announces it intends to consolidate the Company's issued share capital on a ratio of one (1) new post-consolidated common share for every te...

REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in Februa...

Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q3 GAAP EPS of -$0.58 misses by $0.01 . Revenue of $2.1M (+162.5% Y/Y) beats by $0.87M . For further details see: Bolt Biotherapeutics GAAP EPS of -$0.58 misses by $0.01, revenue of $2.1M beats by $0.87...

– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 – BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022 – Cash balance of $209.6 million anticipated to fund key milestones through 2025 ...

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical data on BDC-30...

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Stife...

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morga...

Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q2 GAAP EPS of -$0.61 beats by $0.08 . Revenue of $1.39M beats by $0.89M . For further details see: Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year – New portfolio prioritization and capital allocation strategy extends expected cash runway by an additional two years – Cash b...